John Ford, Enterprise Therapeutics CEO

Ex­clu­sive: UK biotech rais­es $33.1M to test CF drug that could work on top of stan­dard of care

En­ter­prise Ther­a­peu­tics closed a £26 mil­lion Se­ries B round to fund a Phase IIa tri­al of its cys­tic fi­bro­sis drug, which aims to sig­nif­i­cant­ly im­prove hy­dra­tion and clear away the mu­cus that makes breath­ing dif­fi­cult for these pa­tients.

Panakes Part­ners led the round, along with par­tic­i­pa­tion from big-name ex­ist­ing in­vestors like Ver­sant Ven­tures, No­var­tis Ven­ture Fund and For­bion.

The UK-based biotech plans to dose the first pa­tient with ETD001, its lead drug, in a Phase IIa tri­al around East­er, CEO John Ford told End­points News, with the first batch of da­ta set to come out in mid-2025. The tri­al, which will be con­duct­ed in the UK and Eu­rope, has al­ready se­cured reg­u­la­to­ry ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA